Hepion Pharmaceuticals ( (HEPA) ) has released a notification of late filing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hepion Pharmaceuticals, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the ongoing process of compiling necessary information, which could not be completed without unreasonable effort and expense. The company anticipates filing the report within a 15-day extension period. Financially, Hepion Pharmaceuticals expects significant changes in its results, notably a decrease in research and development expenses by $23.5 million, primarily due to reduced clinical trial costs and headcount. General and administrative expenses also decreased by $2.4 million. The notification was signed by John Brancaccio, the Interim Chief Executive Officer, who assured ongoing compliance efforts.
More about Hepion Pharmaceuticals
YTD Price Performance: -98.17%
Average Trading Volume: 1,118,239
Technical Sentiment Signal: Strong Buy
Current Market Cap: $518.4K
For a thorough assessment of HEPA stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money